• ChemoMetec’s Q1 2026/27 EBITDA jumped 46% year-over-year to DKK 100.3 million, driven by higher revenue, strict cost control and improved gross margins.
• Revenue rose 28% year-over-year to DKK 160 million, with growth across all product segments.
• Revenue from instruments climbed 61% year-over-year to DKK 65.6 million, primarily driven by higher demand for the XcytoMatic range.
• NC-203 revenue exceeded DKK 20 million, with market penetration faster than anticipated.
• Maintained 2026/27 guidance for revenue of DKK 570–605 million and EBITDA of DKK 335–360 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ChemoMetec A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051141OMX_____CNEWS_EN_GNW1001302092_en) on November 05, 2026, and is solely responsible for the information contained therein.